Kailera Therapeutics (NASDAQ:KLRA) Sets New 52-Week Low – Should You Sell?

Kailera Therapeutics, Inc. (NASDAQ:KLRA) shares hit a new 52-week low during trading on Tuesday . The stock traded as low as $11.84 and last traded at $11.99, with a volume of 1050237 shares changing hands. The stock had previously closed at $12.83.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. Wall Street Zen cut shares of Kailera Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. Weiss Ratings initiated coverage on Kailera Therapeutics in a research report on Friday, August 14th. They set a “sell (d)” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $42.75.

Kailera Therapeutics Price Performance

The company’s 50-day moving average price is $16.62. The company has a market cap of $1.70 billion and a price-to-earnings ratio of -0.00.

Kailera Therapeutics (NASDAQ:KLRA) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.35). On average, analysts anticipate that Kailera Therapeutics, Inc. will post -3.89 EPS for the current year.

Institutional Investors Weigh In On Kailera Therapeutics

Several hedge funds have recently made changes to their positions in KLRA. Atlas Venture Life Science Advisors LLC purchased a new position in Kailera Therapeutics in the second quarter worth $113,923,000. Wellington Management Group LLP purchased a new stake in shares of Kailera Therapeutics in the second quarter valued at about $64,308,000. Frazier Life Sciences Management L.P. purchased a new position in Kailera Therapeutics during the second quarter worth $24,233,000. State Street Corp purchased a new stake in Kailera Therapeutics during the 2nd quarter worth about $19,126,000. Finally, Squarepoint Ops LLC purchased a new position in shares of Kailera Therapeutics during the second quarter valued at approximately $993,000.

About Kailera Therapeutics

Kailera Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for obesity and related metabolic diseases. The company’s programs are designed to address the substantial medical needs associated with excess weight and metabolic disorders.

Kailera’s lead product candidate is KAIL-001, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist intended for the treatment of obesity and potentially related conditions. The company is advancing its pipeline through clinical development and regulatory activities, although its products remain investigational and are not yet approved for commercial use.

The company’s operations are centered on the development of therapies for global markets.